Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This review discusses therapeutic options for androgenetic alopecia, noting that while antiandrogen treatments prevent further hair loss and promote some regrowth, dramatic results are rare.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This study found that Physcion from Polygonum multiflorum may be an effective natural 5α-reductase inhibitor for treating androgenic alopecia by enhancing hair growth and improving follicle morphology in laboratory settings.

This study found that dutasteride increased hair growth metrics significantly more than finasteride in Korean men with AGA, but a meta-analysis suggests no overall significant efficacy difference between the two drugs.

This study conducted an in silico evaluation of Korean herbal compounds against key targets involved in androgenetic alopecia, finding Biochanin A, Saponin Re, and Emodin as promising candidates for topical treatments, but highlighting safety and topical formulation challenges.

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

This article presents the SH-1 molecule as a novel AR antagonist for androgenetic alopecia treatment, highlighting its tissue-specific action and potential for commercialization, but provides no new clinical results.

This review provides an overview of clinically approved small molecule drugs targeting androgen receptors and discusses therapeutic applications, without presenting new experimental results.

Clascoterone safely promotes hair growth similar to minoxidil.

This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.

This review outlines that minoxidil (topical and oral) and 5α-reductase inhibitors are the most effective treatments for androgenetic alopecia, with additional therapies like platelet-rich plasma and hair transplantation enhancing results, emphasizing the need for individualized, combination approaches.

In this study, in silico analysis identified Saponin Re and Emodin as promising candidates for topical treatment of androgenetic alopecia, with Biochanin A having the most favorable safety profile among the tested compounds.

In this study, a newly developed cardamonin-loaded liposomal formulation significantly enhanced hair growth and improved hair follicle performance in mice with androgenic alopecia.

In AGA animal models, this study found that finasteride-loaded microspheres provided rapid and sustained dihydrotestosterone suppression, promoting hair regrowth through dual-phase drug release.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.

In this study, Cyanidin 3-O-arabinoside was found to protect against DHT-induced dermal papilla cell senescence and mitochondrial dysfunction in androgenetic alopecia, restoring hair growth in mouse models.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

This study identified a novel class of nonsteroidal ligands that can mimic the effects of dihydrotestosterone on androgen receptors, suggesting potential therapeutic applications in male fertility and hormone replacement therapy.

This study used a multi-layer in silico framework to evaluate Korean herbal compounds for androgenetic alopecia, identifying Biochanin A, Saponin Re, and Emodin as potential topical candidates with distinct safety and affinity profiles, although these findings remain purely computational without experimental validation.

This study mapped potential targets and pathways for baicalin's action in androgenic alopecia, suggesting it may inhibit 5α-reductase and serve as an effective treatment ingredient.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

This study found that the leaf extract of Tectona grandis and its major bioactive constituents moderately inhibit the 5α-reductase enzyme, which is linked to androgenetic alopecia, and also possess anti-inflammatory properties, showing promise as dual-action candidates for managing this condition.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.